Tiziana Life Sciences to retain Dr. Napoleone Ferrara August 20, 2020 – Posted in: Uncategorized

20th August 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana is Pleased to Retain Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board for an Additional Three-Year Term – Dr. Ferrara is the discoverer of Avastin® and Lucentis®, multi-billion dollars antibody drugs from Genentech – A member of National Academy of Sciences and recipient of several prestigious awards, including the Lasker award. Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the…

Tiziana Life Sciences – Patent Granted August 18, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease 18 August, 2020 Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office (“USPTO”) has granted a patent on use and methods of treatment…

Tiziana Life Sciences (TILS) – Closing of $57.25 Million Offering August 5, 2020 – Posted in: Minexia - NR Private Market, Tiziana Life Sciences (TILS)

5th August, 2020 Tiziana Life Sciences plc Announces Closing of $57.25 Million Offering London, New York 5 August 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces the closing of its registered direct offering (the “Offering”) of American Depositary Shares (“ADSs”) on the NASDAQ Global Market. As announced on 3 August 2020, Tiziana issued 11,009,615…

Tiziana Life Sciences (TILS)- Issue of Equity August 3, 2020 – Posted in: Tiziana Life Sciences (TILS)

Monday 3rd August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million New York and London, August 3, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced it has entered into definitive agreements with investors for the purchase and sale of 11,009,615 of the Company’s American Depositary Shares…

Tiziana Announces Submission of Patent Application on Use of Foralumab July 16, 2020 – Posted in: Tiziana Life Sciences (TILS)

16 July 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy New York/London, July 16, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has submitted a…

Tiziana Life Sciences – Interview to Air on Bloomberg Intl July 10, 2020 – Posted in: Tiziana Life Sciences (TILS)

10 July 2020 Tiziana Life Sciences plc Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report NEW YORK and LONDON, July 10, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced an interview with Kunwar Shailubhai, Ph.D., the Company’s CEO and CSO, will air on The RedChip Money Report television program. The interview will air Sunday,…

Tiziana Life Sciences – Totoal Voting Rights & StemPrintER Demerger Update July 1, 2020 – Posted in: Tiziana Life Sciences (TILS)

Wednesday 1st July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Total Voting Rights and StemPrintER Demerger Update London, New York, 1 July 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that plans to effect the demerger of StemPrintER from the Group are continuing to be progressed and…

Tiziana Life Sciences – Agreement with STC Biologics June 29, 2020 – Posted in: Tiziana Life Sciences (TILS)

Monday 29th June, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Agreement with STC Biologics Tiziana Life Sciences Announces Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19. · This proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19 New York/London – 29…

Tiziana Life Sciences plc – Exercise of Warrants and Issue of Equity and Total Voting Rights June 22, 2020 – Posted in: Tiziana Life Sciences (TILS)

Monday 22nd June, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Exercise of Warrants and Issue of Equity and Total Voting Rights London, New York, 22 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has allotted and issued 1,800,000 ordinary shares of 3 pence each (“New Ordinary Shares”)…

Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases June 19, 2020 – Posted in: Tiziana Life Sciences (TILS)

Friday 19th June, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases · First-ever granted patent on oral administration of anti-CD3 monoclonal antibodies for immunotherapies · Transformational oral formulation technologies applicable to other antibodies This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 19 June 2020…